Search

Repligen Corp

Chiusa

SettoreSettore sanitario

141.05 -1.55

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

140.31

Massimo

143.62

Metriche Chiave

By Trading Economics

Entrata

-5M

8.3M

Vendite

-3.7M

194M

P/E

Media del settore

144.022

64.641

EPS

0.48

Margine di Profitto

4.29

Dipendenti

2,000

EBITDA

-13M

32M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+20.5% upside

Dividendi

By Acuity

Utili prossimi

27 ott 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

726M

7.4B

Apertura precedente

142.6

Chiusura precedente

141.05

Notizie sul Sentiment di mercato

By Acuity

50%

50%

155 / 340 Classifica in Healthcare

Repligen Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 lug 2026, 20:02 UTC

Repligen Corp shares are lower today amid broader market pressures and rising US Treasury yields. The stock reached a session low earlier.

30 lug 2026, 21:02 UTC

Repligen Corp shares are higher in after-market trading, buoyed by positive investor sentiment amid a focus on corporate earnings and broader market trends.

29 lug 2026, 16:12 UTC

Repligen Corp shares are lower Wednesday, breaking a trend of higher daily closes. Broader market conditions reflect rising crude oil prices and inflation concerns.

28 lug 2026, 23:21 UTC

Repligen Corp shares are higher in after-market trading, reflecting strong momentum and trading near the upper end of its one-month range.

27 lug 2026, 16:26 UTC

News

Repligen Corporation shares are lower as the company approaches its Q2 earnings report, with analysts projecting 10.7% revenue growth. Current price is $131.96.

24 lug 2026, 19:06 UTC

News

Repligen Corp is under scrutiny as a stock to avoid, with concerns over its $763.3 million revenue and declining operating margins. Shares are trading lower today.

22 lug 2026, 19:25 UTC

News
Event
Social Media

Repligen Corp is acquiring BioLife Solutions for about $1.5 billion, offering $11.25 in cash and stock, with a projected $20 million in synergies.

21 lug 2026, 22:56 UTC

Repligen Corp shares are higher in after-market trading, despite a recent trend of lower closes. Broader market sentiment may be influenced by the Nikkei 225 surge.

20 lug 2026, 18:06 UTC

Repligen Corp shares are higher today, reflecting positive market sentiment despite earlier intraday fluctuations. No specific news was identified to explain the movement.

Confronto tra pari

Modifica del prezzo

Repligen Corp Previsione

Obiettivo di Prezzo

By TipRanks

20.5% in crescita

Previsioni per 12 mesi

Media 169.92 USD  20.5%

Alto 207 USD

Basso 142 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Repligen Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

12

Acquista

3

Mantieni

0

Vendi

Sentiment

By Acuity

155 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat